Jiaying “Ingrid” Liu


Graduate Research Assistant

Office: EBB 3110

Research Focus: Novel Cancer Vaccine Strategy Using Nanoparticles

Cancer vaccines have been investigated as immunotherapies for years to treat various tumor types. The basic idea is to deliver antigens or immune-modulatory adjuvants targeting tumor environment to enhance anti-tumor immune responses in the body. During cancer development, tumor cells utilize several strategies to escape from immune-surveillance and create a permissible microenvironment. Among those strategies, program death factor 1 PD-1/PD-L1 interaction and the secretion of indoleamine-2,3-dioxygenase(IDO) are considered the most powerful immunosuppressive factors. Therefore, we are trying to design innovative nanocarriers and strategies with siRNA targeting at tumor cells and silence the immune-inhibitory genes in order to restore effective anti-cancer immune responses.